Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 941 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Comparator 2 Clear all
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

"Fermented Dairy Beverage on Inflammation/Immune Function in Stressful Exercise"

NCT03099044
View directory record Official record
Conditions
Healthy Subjects
Interventions
Placebo comparator, Single Active dose, Double Active dose
Other
Lead sponsor
Dairy A Day, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Worksite Exercise Interventions for Low Back Injury Prevention in Firefighters

NCT02362243
View directory record Official record
Conditions
Low Back Pain
Interventions
Experimental Intervention, Placebo Comparator
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 24, 2026, 8:11 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Postpartum Urinary Retention With Essential Oils (PURE)

NCT03319498
View directory record Official record
Conditions
Urinary Retention
Interventions
Peppermint Oil Vapor, Mineral Oil Vapor
Other
Lead sponsor
Mount Carmel Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

NCT00195663
View directory record Official record
Conditions
Early Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 4 Interventional Results available

Modafinil for Treatment of Fatigue in ALS Patients

NCT00614926
View directory record Official record
Conditions
Fatigue
Interventions
Modafinil, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03370133
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Ustekinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 24, 2026, 8:11 AM EDT
Active, not recruiting Not applicable Interventional

Peer Recovery Support Services for Individuals in Recovery Residences on MOUD

NCT05616949
View directory record Official record
Conditions
Opioid Use Disorder, Substance Use Disorder
Interventions
Treatment as Usual (TAU) (Arm 1), Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2)
Behavioral
Lead sponsor
Potomac Health Foundations
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)

NCT00759135
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH), Enlarged Prostate
Interventions
2.5 mg NX-1207, 0.125 mg NX-1207, finasteride
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years to 75 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
30
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 4 Interventional Results available

Treating Hearing Loss to Improve Mood and Cognition in Older Adults

NCT03321006
View directory record Official record
Conditions
Hearing Loss, Depression
Interventions
Phonak Audeo B-R 90 hearing aid device (Active), Duloxetine or escitalopram, Audeo B-R 90 hearing aid device (Sham)
Device · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 24, 2026, 8:11 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Not applicable Interventional

Soy Formula Feedings in Healthy, Term Infants

NCT02456831
View directory record Official record
Conditions
Gastrointestinal Tolerance
Interventions
Experimental Infant Formula 1, Experimental Infant Formula 2, Experimental Infant Formula 3, Active Comparator: Control Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
2 Weeks to 9 Weeks
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1994
U.S. locations
7
States / cities
Little Rock, Arkansas • Aurora, Illinois • Owensboro, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 3 Interventional Results available

Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)

NCT03031782
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis
Interventions
secukinumab, placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Boise, Idaho • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

NCT03731182
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Wilmington, Delaware • Atlanta, Georgia • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 24, 2026, 8:11 AM EDT
Active, not recruiting Not applicable Interventional

Vida Sana y Completa Obesity and Food Insecurity Study

NCT05211180
View directory record Official record
Conditions
Obesity
Interventions
Vida Sana, Vida Sana y Completa
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 2 Interventional

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy

NCT01521598
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
SKL11197, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Northport, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM

NCT03646721
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
DA-1241, Placebo, Sitagliptin
Drug
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 2 Interventional

A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)

NCT02083289
View directory record Official record
Conditions
Ocular Hypertension, Open Angle-glaucoma
Interventions
ONO-9054, Latanoprost
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
12
States / cities
Los Angeles, California • Mission Hills, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Steps to Effective Problem Solving in Group Homes

NCT02855008
View directory record Official record
Conditions
Problem Behavior
Interventions
STEPS, Food for Life
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 3 Interventional Results available

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

NCT03443869
View directory record Official record
Conditions
CMV Disease
Interventions
Letermovir, Valganciclovir, Acyclovir (ACV), Placebo to ACV, Placebo to LET, Placebo to VGCV
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 4 Interventional Results available

Advancing Personalized Antidepressant Treatment Using PET/MRI

NCT02623205
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

NCT02106923
View directory record Official record
Conditions
Healthy
Interventions
1 tablet Empagliflozin/2 tablets Metformin XR, 10 mg Empagliflozin/1000 mg Metformin XR, 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR, 2 tablets 5 mg Empagliflozin/750 Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 24, 2026, 8:11 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

NCT06874621
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
VY7523, Placebo Comparator
Drug
Lead sponsor
Voyager Therapeutics
Industry
Eligibility
50 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 8:11 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial

NCT02784392
View directory record Official record
Conditions
Enteral Feeding Intolerance (EFI)
Interventions
Ulimorelin, Metoclopramide
Drug
Lead sponsor
Lyric Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
New Orleans, Louisiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 24, 2026, 8:11 AM EDT